Evidence Based Use of T3+T4 Combinations
|Start date||Days and times|
|3 November 2019||12:30 - 17:30|
Who it’s for
This course is designed for healthcare professionals with interest in thyroid health.
What you’ll learn
This innovative symposium will occur simultaneously in Chicago, US and London, UK, representing a collaborative effort between the ATA, BTA and ETA, to bring together leading experts in this area from North America and Europe. It will be a live meeting in both locations, with the UK audience accessing a webcast to view the US presentations and the US audience accessing a webcast to view the UK presentations with the opportunity for both audiences to ask questions to all speakers.
The symposium will conclude with fully interactive workshops on the use of combination therapy in the UK, and a patient discussion forum in the US. Co-chaired by US based Jacqueline Jonklaas, MD and UK based Colin M. Dayan, MA, FRCP, PhD, the anticipated goal is to use the symposium content and discussion as material to produce a consensus statement about the design of future combination therapy trials and to assist endocrinologists in advising their patients on the current evidence base behind combination therapy.
- The Scientific Background
- Dosing Regimes in Clinical Trials of T3/T4
- Trial Endpoints – Measuring Benefit
- Practical Management of Patients on T3 and NDT
For full details of the programme, download the agenda (see Related Links). For further enquiries, please email the Endocrinology team.
Amba Hotel Marble Arch